Comprehensive comparison of homologous recombination deficiency predictors in early-stage triple-negative breast cancer
Deborah F Nacer, Srinivas Veerla, Iñaki Sasiain, Jari Häkkinen, Johan Vallon-Christersson, Maria Rossing, Serena Nik-Zainal, Anders Edsjö, Johan Staaf · 2026
Read Comprehensive comparison of homologous recombination deficiency predictors in early-stage triple-negative breast cancer by Deborah F Nacer, Srinivas Veerla, Iñaki Sasiain, Jari Häkkinen, Johan Vallon-Christersson, Maria Rossing, Serena Nik-Zainal, Anders Edsjö, Johan Staaf (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13295736.txt.
Description
Deborah F Nacer and colleagues compare seven ways to judge DNA repair weakness in breast cancer in a 2026 study. Triple-negative tumours often carry homologous recombination deficiency, which can guide drug choice. Tests based on DNA, RNA, function, or images had never been compared head-to-head in one fair group.
The group held 235 patients with early disease from southern Sweden, profiled by several data types. Most methods agreed substantially, with sequencing based tools and one scar method aligning closest. Remaining clashes traced to data handling and training that ignored known tumour variety. Survival checks used freedom from invasive disease after standard chemotherapy as the yardstick.
Catalog record
| CREATOR | Deborah F Nacer, Srinivas Veerla, Iñaki Sasiain, Jari Häkkinen, Johan Vallon-Christersson, Maria Rossing, Serena Nik-Zainal, Anders Edsjö, Johan Staaf |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 79604 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |